Sign In
Buy PFE
$25.69
+0.335 (+1.32%)
At Close: Jun 04, 2026
XtalPi and Pfizer Expand Strategic Collaboration to Advance AI-Driven Drug Discovery and Materials Science Simulations
09:23pm, Sunday, 29'th Jun 2025
CAMBRIDGE, Mass. , June 29, 2025 /PRNewswire/ -- XtalPi (2228.HK), a leading global technology company in integrating artificial intelligence (AI) and robotics to advance the discovery of groundbreaki
3 No-Brainer Stocks to Buy for Under $100 Right Now
06:35am, Saturday, 28'th Jun 2025
What's the biggest misconception about investing? The idea that you need a lot of money to get started is certainly a contender.
5 Recession-Proof Dividend Stocks With Yields Over 6%
04:15pm, Friday, 27'th Jun 2025
When the economy is barreling toward a recession, investors' first line of defense might be to abandon ship altogether.
PFE's Hympavzi Phase III Hemophilia Study With Inhibitors Meets Goal
12:00pm, Friday, 27'th Jun 2025
Pfizer's Hympavzi meets key phase III goals, demonstrating a significant reduction in bleeding in hemophilia patients with inhibitors.
All You Need to Know About Pfizer (PFE) Rating Upgrade to Buy
01:01pm, Thursday, 26'th Jun 2025
Pfizer (PFE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Pfizer's bleeding disorder therapy meets main goal in patients with certain antibodies
07:23am, Thursday, 26'th Jun 2025
Pfizer said on Thursday its hemophilia therapy, Hympavzi, met the main goal of a late-stage study in patients with certain types of antibodies.
Pfizer Announces Positive Topline Phase 3 Results for HYMPAVZI™ in Hemophilia A or B with Inhibitors
06:45am, Thursday, 26'th Jun 2025
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 BASIS study (NCT03938792) evaluating HYMPAVZI™ (marstacimab) for adults and adolescents l
Pfizer Could Be The Turnaround Story In The Pharmaceutical Space
11:57pm, Wednesday, 25'th Jun 2025
Pfizer's post-pandemic revenue decline is temporary; new launches like Abrysvo and Adcetris, plus Seagen integration, position it for a 2025 turnaround. Valuation is compelling: Pfizer trades at deep
Pfizer Declares Third-Quarter 2025 Dividend
05:30pm, Wednesday, 25'th Jun 2025
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 third-quarter 2025 dividend on the company's common stock, payable September 2, 2025, to
Don't Sleep On Pfizer: The Turnaround Is Just Getting Started
02:15pm, Wednesday, 25'th Jun 2025
Despite a revenue miss, Pfizer's Q1 earnings crushed estimates due to aggressive, structural cost-cutting, signaling a powerful shift towards operational and margin excellence. Management is expanding
17 Ideal 'Safer' Dividend Dogs To Buy Out Of 72 June Graham Value All-Stars
02:15pm, Wednesday, 25'th Jun 2025
I use YCharts' Value Score and Ben Graham Formula Value All Stars, or GASV, to identify large-cap stocks offering strong value and dividend safety. Seventeen out of twenty-four "safer" lowest-priced D
Top stock price forecast: Plug Power, Uber, and Pfizer
12:06pm, Wednesday, 25'th Jun 2025
The US stock market bounced back on Tuesday after the truce between Iran and Israel. The Dow Jones, Nasdaq 100, and S&P 500 indices jumped by over 1%, and the bullish momentum continued in the futures
Pfizer Invites Public to View and Listen to Webcast of August 5 Conference Call with Analysts
10:00am, Wednesday, 25'th Jun 2025
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EDT on Tuesday,
Boomers Are Snapping Up 4 Super-Safe Passive Income Stocks Under $30
07:14am, Wednesday, 25'th Jun 2025
Baby Boomers love dividend stocks because they provide dependable passive income streams and an excellent opportunity for solid total return.
Pfizer (PFE) Surpasses Market Returns: Some Facts Worth Knowing
06:46pm, Tuesday, 24'th Jun 2025
In the closing of the recent trading day, Pfizer (PFE) stood at $24.31, denoting a +1.17% move from the preceding trading day.
